Nikhil C. Munshi MD
Adjunct Associate Professor, Hematology & Medical Oncology
72 E. Concord Street nikhil.munshi@va.gov
Sections
Hematology & Medical Oncology
Biography
Dr. Nikhil Munshi received his medical degree from Maharaja Sayajirao University, followed by an internship and residency in internal medicine at Shri Sayaji General Hospital and Maharaja University in India. He then completed an oncology fellowship at Johns Hopkins Ocology Center, and an hematology/oncology fellowhip at Indiana University Medical Center. Dr. Munshi is currently professor of medicine in the Department of Medicine at Harvard Medical School, as well as an attending physician at VA Boston Healthcare System and Dana-Farber Cancer Institute.
A diplomate of American Board of Internal Medicine, Dr. Munshi is also on the Board of Directors of the International Myeloma Society. He is a member of numerous professional associations including the Indian Medical Association, Physician’s Association of India, Indian Association of Clinical Oncology, American Medical Association, American Society of Clinical Oncology, and the American Society of Hematology, among others. In addition, he is on the editorial board of Clinical Lymphoma and Myeloma and Personalized Medicine in Oncology and is an ad hoc reviewer for numerous professional journals.
Dr. Munshi’s current laboratory research and clinical activities specialize in plasma cell disorders with a focus on understanding oncogenomic changes in myeloma and developing a translational research programs in myeloma. He has also established a Myeloma Initiative at Veterans Administration Hospitals, a comprehensive program bringing together, for the first time, all major VA hospitals across the country to focus on cutting-edge joint clinical studies.
Education
MBBS, Maharaja Sayajirao University
MD, Maharaja Sayajirao University
Publications
Branagan AR, Mo C, Lei M, Gustine JN, Yee AJ, O'Donnell E, Castillo JJ, Nadeem O, Flynn C, Bernstein Z, Nakamoto-Matsubara R, Meid K, Verma R, Hunter ZR, Guerrera ML, Alter G, Burke J, Harrington C, Agyemang E, Gammon M, Lively K, Packer L, Horick N, Laubach J, Mitsiades CS, Munshi N, Anderson KC, Treon SP, Richardson PG, Raje NS, Sarosiek SR. Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemia. Blood Adv. 2025 Sep 23; 9(18):4568-4579. PMID: 40472329.
Published on 9/19/2025Frede J, Poller JC, Shi K, Stuart H, Sotudeh N, Havig C, Lim K, Wiggers CRM, Cho EY, Vijaykumar T, Liu J, Waldschmidt JM, Nair MS, Anand P, Dimitrova V, Montanaro A, Yee AJ, Munshi NC, Anderson KC, Martin N, Kaiser SM, Raab MS, Raje NS, Knoechel B, Lohr JG. The endogenous T cell landscape is reshaped by CAR-T cell therapy and predicts treatment response in multiple myeloma. Leukemia. 2025 Sep 19. PMID: 40973768.
Published on 9/11/2025Perini T, Zordan P, Del Pizzo R, Resnati M, Viviani L, Stefanoni D, Cassina L, Orfanelli U, Trudu M, Oliva L, Lacidogna D, Samur MK, Materozzi M, Drago D, Andolfo A, Patrone M, Degano M, Boletta A, Milan E, Ciceri F, Munshi NC, Bellone M, Cenci S. The mitochondrial protease ClpP is a metabolic vulnerability and an immunogenic trigger against multiple myeloma. Blood. 2025 Sep 11; 146(11):1286-1299. PMID: 40300074.
Published on 9/1/2025La J, Hshieh T, Hamparsumian A, Zwolinski R, Wood J, Dharne M, Gaziano JM, Brophy MT, Do NV, Munshi NC, Driver JA, Abel GA, Fillmore NR, DuMontier C. Potentially Inappropriate Medications, Frailty, and Outcomes in Patients With Cancer Managed in a National Health Care System. J Natl Compr Canc Netw. 2025 Sep; 23(9):363-370. PMID: 40930142.
Published on 8/26/2025Little JS, Medina Pena A, Kim EB, Yee AJ, Nadeem O, Midha S, Sperling AS, Munshi NC, Raje N, Frigault MJ, Cirstea DD, Hammond SP. Invasive fungal disease is rare in patients with relapsed/refractory multiple myeloma treated with BCMA CAR T-cell therapy. Blood Adv. 2025 Aug 26; 9(16):4190-4194. PMID: 40561525.
Published on 8/26/2025Frenking JH, Zhou X, Rejeski K, Wagner V, Costello P, Hielscher T, Gatti L, Kauer J, Nadeem O, Mai EK, Michel CS, Friedrich MJ, Sedloev D, Weinhold N, Goldschmidt H, Herfarth K, Schmitt A, Hundemer M, Schmitt M, Müller-Tidow C, Topp M, Einsele H, Dreger P, Munshi NC, Sperling AS, Rasche L, Sauer S, Raab MS. Bridging intensity is associated with impaired hematopoietic recovery after BCMA CAR-T therapy for multiple myeloma. Blood Adv. 2025 Aug 26; 9(16):4151-4166. PMID: 40267180.
Published on 8/14/2025Morelli E, Aktas-Samur A, Maisano D, Gao C, Favasuli V, Papaioannou D, De Nola G, Henninger JE, Liu N, Turi M, Folino P, Vreux L, Cumerlato M, Chen L, Aifantis I, Fulciniti M, Anderson KC, Lytton-Jean AKR, Gullà A, Young RA, Samur MK, Munshi NC. CRISPR-Cas13d functional transcriptomics reveals widespread isoform-selective cancer dependencies on lncRNAs. Blood. 2025 Aug 14; 146(7):847-860. PMID: 40403231.
Published on 8/4/2025Rivera J, Yan Q, Daneshmandi S, Lannes R, Katsuta E, Choi JE, Singh PK, Belal A, Alberico R, Lund I, Schaefer M, Hassan H, Parker S, Anderson KC, Munshi NC, Samur MK, McCarthy PL, Hillengass J, Mohammadpour H. Deciphering neutrophil dynamics in the focal lesion tumor microenvironment to overcome immunosuppression in multiple myeloma. Blood. 2025 Aug 04. PMID: 40758944.
Published on 7/31/2025Richardson PG, Munshi NC, Longo DL. Opening the Door to Tailored Treatment in Newly Diagnosed Multiple Myeloma. N Engl J Med. 2025 Jul 31; 393(5):498-500. PMID: 40742264.
Published on 7/15/2025Martin N, Thompson E, Stong N, Xu Y, Finney O, Rytlewski J, Flynt E, Marfo J, Descalzi-Montoya DB, Manrique I, Paiva B, Munshi N, Campbell TB, Kaiser SM. Distinct patient, tumour and chimeric antigen receptor T-cell characteristics are associated with initiating versus sustaining responses to idecabtagene vicleucel in relapsed and refractory multiple myeloma. Br J Haematol. 2025 Sep; 207(3):1019-1028. PMID: 40665490.